Endex Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Endex Capital Management’s Portfolio BMY Stock Details BMY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2013 Q4	$880K	Hold	16,551	–	–	0.82%	27
2013 Q3	$766K	Hold	16,551	–	–	0.79%	29
2013 Q2	$740K	Buy	+16,551	New	+$719K	0.79%	26

Other funds holding BMY

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Endex Capital Management's BMY Position: Q4 2013 in Review

Endex Capital Management held its Bristol-Myers Squibb (BMY) position steady in Q4 2013 at 16,551 shares worth $880K. The position accounts for 0.82% of the portfolio, ranked #27.

Endex Capital Management first reported a position in BMY in Q2 2013 and has held it in 3 quarters since. 1,314 funds tracked by Wall St. Rank hold BMY as of Q4 2013.

Endex Capital Management held 16,551 shares of Bristol-Myers Squibb worth $880K as of Q4 2013.
Endex Capital Management left its Bristol-Myers Squibb share count unchanged in Q4 2013.
Bristol-Myers Squibb made up 0.82% of Endex Capital Management's portfolio in Q4 2013, its #27 holding.
Endex Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 3 quarters since.
1,314 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q4 2013.

Based on Endex Capital Management's 13F filing for Q4 2013, filed 14 Feb 2014.